PROMISING RESULTS FOR LENALIDOMIDE PLUS DEXAMETHASONE IN MYELOMA

The pharmaceutical journal group

首页> 外文期刊>The pharmaceutical journal >PROMISING RESULTS FOR LENALIDOMIDE PLUS DEXAMETHASONE IN MYELOMA

【24h】

PROMISING RESULTS FOR LENALIDOMIDE PLUS DEXAMETHASONE IN MYELOMA

机译：来那度胺加地塞米松在骨髓中的有希望的结果

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

Triple therapy with melphalan, prednisone and thalidomide (MPT) is the current standard of oare for patients with myeloma who are ineligible for stem-oell transplantation. This may change following publication in The New England Journal of Medicine (online, 4 September 2014) of data on a promising new combination therapy, lenalidomide plus dexamethasone (LD).

机译：对于那些不适合干细胞移植的骨髓瘤患者，美法仑，泼尼松和沙利度胺（MPT）的三联疗法是目前的燕麦标准。在《新英格兰医学杂志》（在线，2014年9月4日）上发表有关有希望的新联合治疗方案来那度胺联合地塞米松（LD）的数据后，情况可能会有所改变。

著录项

来源
《The pharmaceutical journal》 |2014年第7828期|共1页
作者
The pharmaceutical journal group;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类
关键词

相似文献

外文文献
中文文献
专利

1. Rationale and design of the German-Speaking Myeloma Multicenter Group (GMMG) trial ReLApsE: a randomized, open, multicenter phase III trial of lenalidomide/dexamethasone versus lenalidomide/dexamethasone plus subsequent autologous stem cell transplantation and lenalidomide maintenance in patients with relapsed multiple myeloma [J] . Marc-Andrea Baertsch, Jana Schlenzka, Elias K. Mai, BMC Cancer . 2016,第1期

机译：德语德语骨髓瘤多中心小组（GMMG）试验ReLApsE的原理和设计：来那度胺/地塞米松与来那度胺/地塞米松联合随后自体干细胞移植和来那度胺维持治疗多发性骨髓瘤患者的随机，开放，多中心III期试验
2. Elderly multiple myeloma (MM) patients, who are generally ineligible for transplantation, have high risks of death and treatment discontinuation, and require a regimen incorporating novel agents that balance safety, tolerability, and efficacy. We evaluated alternating bortezomib-dexamethasone and lenalidomide-dexamethasone treatments administered over a 63-day cycle in transplant-ineligible elderly patients with newly diagnosed MM. Subcutaneous bortezomib 1.3 mg/m2 was administered weekly on Days 1, 8, 15, and 22; oral lenalidomide 15 mg daily on Days 36-56; and oral dexamethasone 20 mg on Days 1, 8, 15, 22, 36, 43, 50, and 57 for 6 cycles. The primary endpoint was the overall response rate. [J] . Yokoyama Akihiro, Kada Akiko, Saito Akiko M., Acta medica Okayama . 2019,第6期

机译：通常不适合移植的老年多发性骨髓瘤（MM）患者具有很高的死亡和中止治疗的风险，因此需要一种方案，该方案应采用能够平衡安全性，耐受性和疗效的新型药物。我们评估了在不适合移植的老年初诊MM患者中，硼替佐米-地塞米松和来那度胺-地塞米松在63天周期内的交替治疗。在第1、8、15和22天每周一次皮下注射硼替佐米1.3 mg / m2;在第36-56天每天口服来那度胺15 mg;在第1、8、15、22、36、43、50和57天，口服地塞米松20 mg，共6个周期。主要终点是总体缓解率。
3. A comparison of lenalidomide/dexamethasone versus cyclophosphamide/lenalidomide/dexamethasone versus cyclophosphamide/bortezomib/dexamethasone in newly diagnosed multiple myeloma [J] . KhanM.L., ReederC.B., KumarS.K., British Journal of Haematology . 2012,第3期

机译：来那度胺/地塞米松与环磷酰胺/来那度胺/地塞米松与环磷酰胺/硼替佐米/地塞米松的比较在新诊断的多发性骨髓瘤中
4. Proteomic alterations caused by treatment with Bortezomib, Doxorubicin, and Dexamethasone in Myeloma [C] . Dominik Dytfeld, Vadiraja B. Bhat, Malathi Hari, American Society for Mass Spectrometry Conference on Mass Spectrometry and Allied Topics . 2009

机译：用髓质族，多柔比星和地塞米松治疗引起的蛋白质组学改变
5. Characterization of a dexamethasone-resistant 7TD1 murine myeloma cell line. [D] . Gangavarapu, Kalyan J. 2008

机译：地塞米松抗性7TD1鼠骨髓瘤细胞系的表征。
6. Rationale and design of the German-Speaking Myeloma Multicenter Group (GMMG) trial ReLApsE: a randomized open multicenter phase III trial of lenalidomide/dexamethasone versus lenalidomide/dexamethasone plus subsequent autologous stem cell transplantation and lenalidomide maintenance in patients with relapsed multiple myeloma [O] . Marc-Andrea Baertsch, Jana Schlenzka, Elias K. Mai, 2016

机译：德语德语骨髓瘤多中心小组（GMMG）试验ReLApsE的原理和设计：来那度胺/地塞米松与来那度胺/地塞米松联合随后自体干细胞移植和来那度胺维持治疗多发性骨髓瘤的患者的随机开放多中心III期试验
7. Rationale and design of the German-Speaking Myeloma Multicenter Group (GMMG) trial ReLApsE : a randomized, open, multicenter phase III trial of lenalidomide/dexamethasone versus lenalidomide/dexamethasone plus subsequent autologous stem cell transplantation and lenalidomide maintenance in patients with relapsed multiple myeloma [O] . Bärtsch, Marc-Andrea, Schlenzka, Jana, Mai, Elias K., 2017

机译：德语系骨髓瘤多中心小组（RelepsE）试验的原理和设计：来那度胺/地塞米松与来那度胺/地塞米松联合随后的自体干细胞移植和来那度胺维持治疗多发性骨髓瘤的患者的随机，开放，多中心III期试验

PROMISING RESULTS FOR LENALIDOMIDE PLUS DEXAMETHASONE IN MYELOMA

摘要

著录项

相似文献

相关主题

期刊订阅